Comparative Pharmacology
Head-to-head clinical analysis: LO LOESTRIN FE versus MONO LINYAH.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LO LOESTRIN FE versus MONO LINYAH.
LO LOESTRIN FE vs MONO-LINYAH
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of ethinyl estradiol and norethindrone acetate suppresses gonadotropin-releasing hormone (GnRH) from the hypothalamus, reducing luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary, thereby inhibiting ovulation. The progestin component thickens cervical mucus, impeding sperm penetration, and alters endometrial receptivity. Ferrous fumarate provides supplemental iron.
Monoclonal antibody that binds to and inhibits the activity of interleukin-23 (IL-23), a pro-inflammatory cytokine involved in immune-mediated inflammatory diseases.
One tablet orally once daily. Each tablet contains norethindrone acetate 1 mg and ethinyl estradiol 10 mcg (24 active tablets) followed by ferrous fumarate 75 mg (2 inactive tablets).
10 mg orally once daily
None Documented
None Documented
Norethindrone: ~8 hours (range 5–12 h); Ethinyl estradiol: ~14 hours (range 10–20 h). Terminal half-life supports once-daily dosing with steady-state reached within 7–14 days.
Terminal elimination half-life is 3–5 hours in adults; prolonged to 8–15 hours in renal impairment (CrCl <30 mL/min) and in neonates.
Renal (primarily as glucuronide conjugates of norethindrone and ethinyl estradiol): ~40% norethindrone metabolites, ~30% ethinyl estradiol metabolites; Fecal: ~30% norethindrone metabolites, ~40% ethinyl estradiol metabolites.
Predominantly renal as unchanged drug (≥90%); minor biliary/fecal (<5%).
Category C
Category C
Combination Oral Contraceptive
Combination Oral Contraceptive